Bicycle Therapeutics plc American Depositary Shares (BCYC)

About BCYC

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

288

Website

www.bicycletherapeutics.com/

Fundamentals

1-day range

$4.03$4.16

Market cap

$277.87M

P/E (trailing)

—

P/E (forward)

-1.86

EPS (trailing)

$-2.74

Dividend yield

—

Beta

1.68

Avg. volume

426.5K

Forecasts

6 analyst ratings

Bicycle Therapeutics plc American Depositary Shares Competitors

Chosen by industry and closest market cap.

• BCYC

  Bicycle Therapeutics plc American Depositary Shares

  $4.21

  ▼ 2.77%
  Market cap $277.87MP/E —
  $3.75$9.16
• EBS

  Emergent BioSolutions Inc. Common Stock

  $5.91

  ▼ 0.51%
  Market cap $273.98MP/E —
  $4.36$14.06
• CAMP

  CAMP4 Therapeutics Corporation Common Stock

  $4.16

  ▲ 0.36%
  Market cap $282.25MP/E —
  $1.41$7.75
• ADAG

  Adagene Inc. American Depositary Shares

  $3.68

  ▼ 5.64%
  Market cap $273.45MP/E —
  $1.3$4.85
• ALXO

  ALX Oncology Holdings Inc. Common Stock

  $2

  ▼ 2.44%
  Market cap $283.93MP/E —
  $0.96$2.66
• FULC

  Fulcrum Therapeutics Inc. Common Stock

  $3.85

  ▲ 0.00%
  Market cap $287.64MP/E —
  $2.83$15.74
• IMRX

  Immuneering Corporation Class A Common Stock

  $4.99

  ▼ 4.22%
  Market cap $288.55MP/E —
  $3.86$10.08

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting
  SeekingAlpha · 8/4/2026

• Michael Charles Ferguson Hannay · July 15, 2026 · Grant

  60.0K
• Travis Alvin Thompson · July 15, 2026 · Grant

  60.0K
• Michael Skynner · July 15, 2026 · Grant

  60.0K
• Jennifer Scott Perry · July 15, 2026 · Grant

  60.0K
• Jennifer Scott Perry · July 6, 2026 · Sale

  333 @ $4.34
• Jennifer Scott Perry · July 6, 2026 · Sale

  43 @ $4.31
• Michael Charles Ferguson Hannay · July 6, 2026 · Sale

  255 @ $4.31
• Travis Alvin Thompson · July 6, 2026 · Sale

  104 @ $4.31
• Kevin Lee · July 6, 2026 · Sale

  1.7K @ $4.31
• Michael Skynner · July 6, 2026 · Sale

  532 @ $4.31
• Jennifer Scott Perry · July 2, 2026 · Sale

  1.0K @ $4.27
• Michael Charles Ferguson Hannay · July 2, 2026 · Sale

  1.5K @ $4.27
• Travis Alvin Thompson · July 2, 2026 · Sale

  819 @ $4.27
• Kevin Lee · July 2, 2026 · Sale

  5.9K @ $4.27
• Michael Skynner · July 2, 2026 · Sale

  1.9K @ $4.27

Institutional Ownership

March 31, 2026

Total shares held

37.83M

Total value held

$161.05M

Institutional holders

96